AMAT
Applied Materials, Inc.
AMAT has a slight edge over OSCR overall, supported by lower modeled downside and stronger modeled upside.
OSCR
Oscar Health, Inc.
OSCR offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
AMAT Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
AMAT's revenue, profitability, cash flow and balance sheet are all currently strong.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
AMAT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 16x | $205 | -46% |
| Forward | 20x | $381 | — |
| Fair | 21x | $263 | -31% |
| Expensive | 29x | $365 | -4.1% |
| Current | 30x | $381 | — |
Historical ranges are pointers, not guarantees.
AMAT's PE is 30x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over AMAT in the historical PE scenario, which offers more potential upside but is not a forecast.
AMAT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| Moderate |
Analysts expect strong earnings and revenue growth for AMAT, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
AMAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $18.83 | +49% |
| Q4 2026 | $12.62 | +46% |
AMAT's earnings per share have climbed steadily: $12.62 over the past year, up 46% from the year before, and higher year over year every quarter since late 2026. Its recent earnings include one-off gains.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over AMAT in the latest year-over-year earnings comparison.
AMAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2026 | $10.4B | +53% |
| Q3 2026 | $9.1B | +25% |
| Q2 2026 | $7.9B | +11% |
| Q1 2026 | $7B | -2.1% |
AMAT's revenue is growing: $10.4B last quarter, up 53% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | +3.2 points |
| Q2 2026 | 32% | +1.3 points |
| Q1 2026 | 26% | -4.2 points |
| Q4 2025 | 25% | N/A |
| Q3 2025 | 31% | N/A |
| Q2 2025 | 31% | N/A |
| Q1 2025 | 30% | N/A |
AMAT has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over AMAT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
AMAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.3B | +14% |
| Q2 2026 | $210M | -80% |
| Q1 2026 | $1B | +91% |
AMAT and OSCR do not have enough comparable growth data to identify a winner.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
AMAT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +1M shares |
| 1 year | -0.2% | -2M shares |
AMAT has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $440M |
| Q2 2026 | $400M |
| Q1 2026 | $337M |
| Q4 2025 | $851M |
| Q3 2025 | $1.1B |
| Q2 2025 | $1.7B |
| Q1 2025 | $1.3B |
AMAT spent $2B buying back its own shares over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
AMAT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.1x | Very low |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | -0.1x | Net Cash |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | 0.2x | Very low |
| Q2 2025 | 0.1x | Very low |
| Q1 2025 | 0.1x | Very low |
AMAT's net debt is less than a year of its operating earnings (EBITDA).
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over AMAT on leverage, with a lower net debt burden relative to earnings.
AMAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.8 | Neutral |
| Stochastic | 13.8 | Oversold |
AMAT's weekly RSI is 43 (neutral) and its Stochastic is 14 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
AMAT PE vs Technology Sector
| Metric | AMAT | Sector median | Relative |
|---|---|---|---|
| PE | 30x | 28x | 8.4% above |
| PE % | 85 | 35 | 50 pts above |
AMAT is trading at 30x earnings, in line with the Technology sector's median of 28x, though its earnings don't support one.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over AMAT on valuation relative to its sector.
AMAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $427.8 | 11% below |
| 20 week MA | $477.9 | 20% below |
| 50 week MA | $418.0 | 8.9% below |
| 100 week MA | $298.5 | 28% above |
| 200 week MA | $232.1 | 64% above |
AMAT has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 64% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over AMAT on trend strength, trading above more of its moving averages.
AMAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $61.2 | $85.3 | +39% |
| 2021 | $85.3 | $155.5 | +82% |
| 2022 | $155.5 | $97.2 | -37% |
| 2023 | $97.2 | $162.1 | +67% |
| 2024 | $162.1 | $166.8 | +2.9% |
| 2025 | $166.8 | $261.9 | +57% |
| 2026 YTD | $261.9 | $381.0 | +45% |
AMAT has finished higher in five of the last six years, three of them by more than 50%. It's up 45% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over AMAT on returns for 2026, with the stronger performance.